In the XB010 + anti–PD-1 groups, the XB010-mediated inhibition of tumor growth was enhanced further, with %TGI of 97% and 96% for XB010 + 0.75 mg/kg anti–PD-1 and XB010 + 5 mg/kg anti–PD-1, respectively (both P < 0.001 vs. control) with CR rates of nine of 10 and five of 10, respectively; Supplementary Table S5). Here, PDCD1 is linked to neoplasm.